Insmed (NASDAQ:INSM – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Insmed to related businesses based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, risk, dividends and profitability.
Profitability
This table compares Insmed and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insmed | -39.85% | -96.38% | -32.55% |
| Insmed Competitors | -12,359.35% | -203.09% | -30.93% |
Earnings & Valuation
This table compares Insmed and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Insmed | $606.42 million | -$1.28 billion | -38.57 |
| Insmed Competitors | $730.85 million | $13.53 million | -10.85 |
Insmed’s rivals have higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Insmed’s rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Insmed and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insmed | 1 | 1 | 23 | 1 | 2.92 |
| Insmed Competitors | 9800 | 15081 | 45386 | 1576 | 2.54 |
Insmed currently has a consensus price target of $196.52, suggesting a potential upside of 80.69%. As a group, “Biotechnology” companies have a potential upside of 104.82%. Given Insmed’s rivals higher probable upside, analysts clearly believe Insmed has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
47.9% of shares of all “Biotechnology” companies are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Insmed rivals beat Insmed on 7 of the 12 factors compared.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
